Psychedelic Research Bulletin: December 2022

Optimi Health Announces Re-Appointments to Board of Directors

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for...

PT381 – DMT, Hierarchies of Complexity, and Reality Switch Technologies

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention...

Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study...

GH Research Reports Third Quarter 2022 Financial Results and Provides Business...

Legally Psychedelic: The Regulatory Environment from Oregon to Colorado

Psychedelics Weekly – Psilocybin-Assisted Psychotherapy for I.B.S., NY Aims to Legalize,...

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101...

Load more